Compare Globus Medical Inc. Class A Common Stock (GMED) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Medtronic PLC — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Medtronic PLC trades at $95.49 (market cap $118.97B). The key difference: Medtronic PLC is far larger — about 11.6× Globus Medical Inc. Class A Common Stock's market cap, and Medtronic PLC pays a 3.1% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Medtronic PLC for 63 Days on average.
| GMED | MDT | |
|---|---|---|
Market Cap | $10.25B | $118.97B |
Volume | 1,108,124 | 24,932,018 |
Sector | Health | Health |
52-Week High | $96.82 | $105.35 |
52-Week Low | $58.33 | $73.75 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $9.76B | $138.31B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, 7% revenue growth in Q1 2026, and a 49-year dividend growth streak. Valuation metrics include a P/E of 22.91 and P/S of 3.19. Recent positive news includes FDA clearances for medical devices and raised full-year guidance, supporting investor confidence.
Outlook remains positive with analyst consensus at Buy (61%) and $97.73 price target. Key opportunities include sustained dividend growth and new product approvals, while risks involve debt increase to 31.11% of assets and competitive pressures. The stock's current level near resistance at $93 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
